Hologic Announces Completion of Loan Repricing
Interest rates on Term Loan A and Revolving Credit Facility reduced by 100
BEDFORD, Mass., March 20, 2013
BEDFORD, Mass., March 20, 2013 /PRNewswire/ --Hologic, Inc. (Hologic or the
Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of
premium diagnostics products, medical imaging systems and surgical products
dedicated to serving the healthcare needs of women, announced today that the
Company completed a repricing of certain loans under the Company's Credit and
Guaranty Agreement (Credit Agreement) dated August 1, 2012.
On March 20, 2013, the Company and several of its domestic subsidiaries
(Guarantors), together with Goldman Sachs Bank USA, as administrative and
collateral agent, and the lenders party thereto entered into Refinancing
Amendment No. 1 (Credit Agreement Amendment).
The Credit Agreement Amendment refinances the Company's existing senior
secured tranche A term loan facility (Term Loan A) and the Company's existing
$300 million senior secured revolving credit facility (Revolving Facility),
each with a maturity date of August 1, 2017, resulting in a 100 basis points
reduction in the interest rates (from 3.00% plus LIBOR to 2.00% plus LIBOR) on
the Term Loan A and the Revolving Facility. In addition, certain covenants and
terms of the Credit Agreement were amended. As of March 20, 2013, the
principal amounts outstanding on the Term Loan A and Revolving Facility were
approximately $975 million and $0, respectively.
Effective today, amounts outstanding under the Term Loan A and the Revolving
Facility initially bear interest, at the Company's option, at: (i) the Base
Rate (as defined in the Credit Agreement) plus 1.00% per annum or (ii) the
Adjusted Eurodollar Rate/LIBOR plus 2.00% per annum. The applicable margin
with respect to the Term Loan A and Revolving Facility are subject to
specified changes depending on the total net leverage ratio, as defined in the
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium
diagnostic products, medical imaging systems, and surgical products.The
Company operates four core business units focused on diagnostics, breast
health, GYN surgical and skeletal health.With a comprehensive suite of
technologies and a robust research and development program, Hologic is
committed to improving lives.The Company is headquartered in Massachusetts.
For more information, visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered trademarks of
Hologic, Inc. and/or its subsidiaries in the United States and/or other
Contacts: Deborah David Cross
Vice President, Investor Relations Vice President &
(781) (781) 999-7789
Senior Director, Investor Relations
SOURCE Hologic, Inc.
Press spacebar to pause and continue. Press esc to stop.